SHREEPAC.BO stock down 18.81% after hours on 17 Feb 2026: watch INR 132 support

The SHREEPAC.BO stock plunged 18.81% in after-hours trading on 17 Feb 2026, closing at INR 133.55 after a one-day drop of INR 30.95. Volume was light at 1,747 shares versus an average of 12,247, which suggests the move came from concentrated trading rather than broad selling. We examine valuation, technicals, Meyka AI grade and short-term forecasts to explain this top-losers move on the BSE in India.

Price action — SHREEPAC.BO stock after hours

SHREEPAC.BO stock moved from a previous close of INR 164.50 to INR 133.55, a drop of 18.81% on 17 Feb 2026 in after-hours trading. The session high was INR 138.95 and the day low was INR 132.00. One-day volume of 1,747 is well below the 30-day average volume of 12,247, which increases the risk of outsized intraday moves.

Fundamentals and valuation for SHREEPAC.BO stock

Shree Pacetronix Limited (SHREEPAC.BO) is listed on the BSE and operates in Healthcare, producing implantable pacemakers and related devices. Key ratios: EPS INR 6.43, PE 21.74, PB 3.19, current ratio 2.10, debt-to-equity 0.32, and market cap INR 513,702,090.00. The stock trades well below its 50-day average of INR 182.84 and 200-day average of INR 160.21, indicating recent momentum weakness.

Technical view and short-term risk for SHREEPAC.BO stock

Technicals show mixed signals. RSI is 41.67, MACD histogram is 3.74, and ADX is 33.93 indicating a strong trend. Bollinger Bands sit at INR 130.20 (lower) and INR 164.21 (upper). Immediate price support is INR 132.00 and resistance near the middle band at INR 147.20. Watch the low liquidity; low trade counts can push volatility higher despite a small float.

Meyka grade and model forecast for SHREEPAC.BO stock

Meyka AI rates SHREEPAC.BO with a score out of 100: 71.50 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly INR 144.80, quarterly INR 138.29, and yearly INR 227.70. Compared with the current price INR 133.55, the model implies a near-term upside of 8.43% (monthly), 3.55% (quarterly), and 70.56% (yearly). Forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context for SHREEPAC.BO stock

Catalysts include any new orders, regulatory approvals for pacemakers, and better-than-expected earnings. Risks are slow receivables (days sales outstanding 162.28), long inventory days (322.53) and very low average trading volume, which heightens volatility. Healthcare sector performance is weaker YTD, so SHREEPAC.BO may follow sector moves on the BSE in India.

Trading checklist and price targets for SHREEPAC.BO stock

Short-term traders should watch INR 132.00 support and a break above INR 147.20 for momentum recovery. Conservative price targets: INR 144.80 (1 month), INR 227.70 (12 months) based on Meyka model. Use position sizing because the stock has a small free float and average volume 12,247 shares. For company details see the company site and the official BSE quote page. Internal reference: SHREEPAC.BO on Meyka.

Final Thoughts

SHREEPAC.BO stock registered a sharp after-hours decline of 18.81% to INR 133.55 on 17 Feb 2026, driven by concentrated selling in a low-volume session. Valuation metrics are mixed: PE 21.74 and PB 3.19 show moderate valuation while liquidity and long inventory days signal operational drag. Meyka AI’s model projects INR 144.80 in one month (+8.43%), INR 138.29 in one quarter (+3.55%), and INR 227.70 in one year (+70.56%) versus the current price. Traders should treat the drop as a high-volatility event and confirm moves with volume and news. These projections are model-based and not guarantees. Use stop-losses and limit position size given the stock’s thin trading and sector sensitivity on the BSE in India.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.